Australian medical technologies to scope the European market
Held in Dusseldorf, Germany, from 16 – 19 November, this years event is expected to attract nearly 140,000 participants.
Other new technologies featured in UniQuests â€˜medtech portfolio include drug delivery and formulation mechanisms; monitoring, diagnostics and screening systems; clinical practice management and training tools; and Allied Health and assistive technologies to help patients recover from stroke, injury and the side effects of disease treatments (full list available on https://www.uniques  t.com.au/medical-devices).
"Medica is the worlds largest medical innovation trade fair, so its the ideal place for showcasing technologies emerging from Australian university research that are addressing global health issues, such as access, aging populations and preventable diseases," said UniQuest Managing Director, David Henderson.
"With about half the delegates from European Union countries and the remainder from Asia, the Americas and Africa, Medica presents a valuable opportunity for UniQuest to talk to major international companies about the competitive edge to be gained from licensing our technologies, and about collaborating with Australian researchers to improve health outcomes around the world.
"Medica also attracts investors looking to be involved with the next blockbuster medical innovation, and the comparative strength of the national economy has positioned Australia within their sights. UniQuest-licensed innovati ons, for example, are now generating annual sales of more than A$3 billion globally, from vaccines like Gardasil to high-tech MRI machines and telehealth systems, so theres a lot of interest in what the research institutions we represent are working on right now to benefit future generations."
UniQuests medical technology portfolio includes innovations from its commercialisation partners: The University of Queensland, University of Technology, Sydney, University of Wollongong, Mater Medical Research Institute, James Cook University, University of Tasmania, and Queensland Health.
UniQuests projects are among the 1000+ Australian biotechnology and medical technology enterprises contributing to the industrys global growth. Of the 151 healthcare and biotech companies listed on the Australian Securities Exchange, 27 were capitalised at greater than A$100 million this year.
About UniQuest Pty Limited
Established by The University of Queensland in 1984, UniQuest is widely recognised as one of Australias largest and most successful university commercialisation groups, benchmarking in the top tier of technology transfer worldwide. From an intellectual property portfolio of 1,500+ patents it has created over 60 companies, and since 2000 UniQuest and its start-ups have raised more than $400 million to take university technologies to market. Annual sales of products using UQ technology and licensed by UniQuest are running at $3 billion. UniQuest now commercialises innovations developed at The University of Queensland and its commercialisation partner institutions: the University of Wollongong, University of Technology Sydney, James Cook University, University of Tasmania, Mater Medical Research Institute, and Queensland Health. UniQuest also provides access to an expansive and exclusive network of independent academics to tailor a consulting or project R&D solution to me et the diverse needs of industry and government, facilitating some 500 consulting, expert opinion, testing, and contract research services each year. UniQuest is also a leading Australasian provider of international development assistance recognised for excellence in technical leadership, management and research. Working with agencies such as AusAID, NZAID, the Asian Development Bank and the World Bank, UniQuest has developed and implemented more than 400 projects in 46 countries throughout the Pacific, South-East Asia, the Indian sub-continent and Africa. www.uniquest.com.au